Enterovirus D68-associated respiratory and neurological illness in Spain, 2014-2018 by Gonzalez-Sanz, Ruben et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=temi20
Emerging Microbes & Infections
ISSN: (Print) 2222-1751 (Online) Journal homepage: https://www.tandfonline.com/loi/temi20
Enterovirus D68-associated respiratory and
neurological illness in Spain, 2014–2018
Rubén González-Sanz, Irene Taravillo, Jordi Reina, Ana Navascués, Antonio
Moreno-Docón, Maitane Aranzamendi, María Pilar Romero, Margarita del
Cuerpo, Carmen Pérez-González, Sonia Pérez-Castro, Almudena Otero &
María Cabrerizo
To cite this article: Rubén González-Sanz, Irene Taravillo, Jordi Reina, Ana Navascués, Antonio
Moreno-Docón, Maitane Aranzamendi, María Pilar Romero, Margarita del Cuerpo, Carmen
Pérez-González, Sonia Pérez-Castro, Almudena Otero & María Cabrerizo (2019) Enterovirus
D68-associated respiratory and neurological illness in Spain, 2014–2018, Emerging Microbes &
Infections, 8:1, 1438-1444, DOI: 10.1080/22221751.2019.1668243
To link to this article:  https://doi.org/10.1080/22221751.2019.1668243
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group, on behalf of Shanghai Shangyixun
Cultural Communication Co., Ltd
Published online: 01 Oct 2019.
Submit your article to this journal Article views: 407
View related articles View Crossmark data
Citing articles: 2 View citing articles 
Enterovirus D68-associated respiratory and neurological illness in Spain,
2014–2018
Rubén González-Sanza, Irene Taravilloa, Jordi Reinab, Ana Navascuésc, Antonio Moreno-Docónd,
Maitane Aranzamendie, María Pilar Romerof, Margarita del Cuerpog, Carmen Pérez-Gonzálezh,
Sonia Pérez-Castroi*, Almudena Oteroa and María Cabrerizo a**
aEnterovirus Unit, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain; bHospital Son Espases, Palma de Mallorca,
Spain; cComplejo Hospitalario de Navarra, Navarra, Spain; dHospital Virgen de la Arrixaca, Murcia, Spain; eHospital Universitario Cruces,
Biocruces Bizkaia Health Research Institute, Bilbao, Spain; fHospital La Paz, Madrid, Spain; gHospital Santa Creu i Sant Pau, Barcelona, Spain;
hHospital Dr. Negrín, Las Palmas de Gran Canaria, Spain; iServicio de Microbiología, Complexo Hospitalario Universitario de Vigo (CHUVI),
Sergas, Vigo, Spain
ABSTRACT
During 2014, enterovirus D68 (EV-D68) outbreaks were described globally, causing severe respiratory diseases in children
and, in some cases, subsequent paralysis. In this study, the type characterization of enterovirus (EV) detected in respiratory
illnesses and the epidemiology and clinical association of EV-D68 infections in Spain over a five-year period were
described. A total of 546 EV-positive samples from hospitalized patients with respiratory infections were included. EV-
D68 was the most frequently detected type (46.6%, 191/410 typed EV). Other EV from species A (25.1%), B (27.8%)
and C (0.5%) were also identified. EV-D68 infections were more associated with bronchitis while EV-A/B types were
more frequent in upper respiratory illness (p < 0.01). EV-D68 was also detected in patients with neurological
symptoms (nine meningitis/meningoencephalitis and eight acute flaccid paralysis cases). Phylogenetic analysis of 3′-
VP1 region showed most Spanish EV-D68 sequences from 2014 to 2016 belonged to subclades B2/B3, as other
American and European strains circulating during the same period. However, those detected in 2017 and 2018
clustered to the emerged subclade D1. In summary, different EV can cause respiratory infections but EV-D68 was the
most prevalent, with several strains circulating in Spain at least since 2014. Association between EV-D68 infection and
neurological disease was also described.
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Introduction
Enteroviruses (EV) are responsible for a wide range of
diseases in humans including febrile illness, myocar-
ditis and neurologic illness, such as aseptic meningitis,
encephalitis or paralysis [1]. EV can be also found in
the respiratory tract and some types, especially from
species C and D cause upper and lower respiratory
symptoms [2]. Since the first isolation in 1962 [3],
Enterovirus D68 (EV-D68) has been associated almost
exclusively with respiratory diseases. It shares similar
biological characteristics with rhinoviruses, which are
currently classified together with EV in the genus
Enterovirus within the Picornaviridae family [4]. EV-
D68 has acid sensitivity and grows at lower optimal
temperatures in some cell lines than other EV [5].
Before 2014, only a few outbreaks or sporadic cases
of EV-D68 infections had been reported in different
parts of the world [6–8]. However, in the late summer
of that year, a large-scale outbreak of severe respiratory
illness associated with EV-D68 was noted in the United
States (US) and Canada [9,10]. Moreover, there was a
significant increase of cases with neurological compli-
cations after the respiratory episode, mainly acute
flaccid myelitis [11].
Since 2014, surveillance of EV-D68 infections is rec-
ommended and several studies have been published in
Europe and other parts of the world regarding EV-D68
circulation, some reflecting an increase in detection in
recent years [12–16]. Additionally, cases of paralysis or
severe myelitis in children, in which EV-D68 was the
only etiologic agent detected, were reported in different
countries, including Spain [17–21]. Regarding respirat-
ory diseases, in our country most of detected EV were
not usually characterized, and the first reports of EV-
D68 detection were published in 2015 [22–24]. There-
fore, the objectives of the present study were first, to
identify the genotype of the EV detected in clinical
samples collected from hospitalized patients with
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different respiratory diseases over a 5-year period, and
second, to describe the molecular epidemiology and
clinical characteristics of EV-D68 infections in Spain.
Patients and methods
Clinical samples. Between April 2014 and December
2018, the Enterovirus Reference Laboratory of the
Spanish National Centre for Microbiology (CNM)
received a total of 546 EV-positive samples from
patients with different respiratory diseases for type
characterization. Patients had been admitted in 17 hos-
pitals from 11 Spanish provinces (Vizcaya, Madrid,
Murcia, Balearic Islands, Zaragoza, Pontevedra, Barce-
lona, Navarra, Canary Islands, Cáceres and Alicante).
Clinical data about diagnosis, underlying diseases,
intensive care unit (ICU) stay and coinfections with
virus other than EVs were kindly provided by the hos-
pitals included in this study. The institutional ethics
board approved the study and informed consent was
obtained from parents or tutors in those cases needed.
Specimens were 526 throat/nasopharyngeal swabs,
18 bronchoalveolar lavages, and 2 stools. The number
of EV-positive respiratory samples received each year
during the study varied: 30 in 2014, 106 in 2015, 258
in 2016, 57 in 2017, and 95 in 2018.
Enterovirus genotyping. RNA was extracted from
clinical samples using the QIAamp Viral RNA Mini
Kit (QIAGEN, Germany). Genotyping was performed
using a previously described RT-nested PCRs in 3’-
VP1 region for EV species A, B and C [25] and sub-
sequent sequencing. In addition, a specific RT-nested
PCR for EV-D68 detection in the same region 3`-
VP1 was designed and evaluated. Primers used in
this case were: outer sense, 5’-CATACCTTAGRTTT-
GATGCTG and outer antisense, 5’-CCATTGAAT
YCCTGGRCCTTC; inner sense, 5’- GTACCMAC
TGGTGCTCTTAC and inner antisense, 5’- CTG
ATTGCCARTCCACATAG. PCR reaction mix,
cycling programme, and sequencing conditions were
the same as previously described for species A, B and
C RT–PCR [25]. An EV-D68 isolate cultured in RD
cells was used to validate the designed RT–PCR. The
virus titre was determined by the median cell culture
infective dose (CCID50/ml) and calculated by the Kär-
ber method [26]. To determine the lower limit of detec-
tion (LoD) of the assay, serial 10-fold dilutions of the
virus, containing 107 CCID50/ml, were analysed. A
set of 15 EV strains from species A to C and four
EV-D68 isolates (obtained in 2010–2011 by inoculating
RD cells with respiratory samples from hospitalized
patients with respiratory illnesses) was analysed for
testing the RT-PCR efficiency (Table 1).
Phylogenetic analysis. A total of 201 EV-D68
sequences obtained in this study and detected between
2014 and 2018 were included in a phylogenetic analysis
with different EV-D68 sequences available in GenBank
in the same 3’-VP1 region from American, Asian and
European countries (N = 89). The prototype strain Fer-
monUS/1962 was included as the outgroup. The phylo-
genetic tree was constructed with MEGA 7.0 software
using a neighbour-joining distance method under the
maximum composite likelihood substitution model
with 1,000 bootstrap resamplings. The sequences
obtained in this study have been deposited in GenBank
under accession numbers MN403103 - MN403299.
Statistical analysis. Clinical characteristics and lab-
oratory variables were compared using the Student’s t
test and Fisher exact test. A 2-sided value of p < 0.05
was considered statistically significant.
Results
LoD and validation of the designed EV-D68 RT-nested
PCR. Using serial dilutions of the assay EV-D68-posi-
tive control, the minimal amount of virus detected by
the specific PCR assay was 1 CCID50/ml. A set of 15
EV strains from species A to C and four EV-D68 iso-
lates was analysed for testing the RT–PCR efficiency.
Only EV-D68-positive samples were amplified
(Table 1). The cross-reactivity with other viruses was
also studied. Rhinoviruses (RV) or human parecho-
viruses (HPeV) were not detected.
EV genotype identification. From the total of 546
EV-positive respiratory samples included in the
study, 410 (75.1%) were successfully amplified with
EV-A, B, C or D68 RT-nested PCRs. RV was identified
in 41 samples and in the remaining 95 untyped EV, the
presence of EV-D68 was excluded by using a RT-
nested PCR in 5´-non-coding region of the EV genome
[27] and subsequent sequencing. EV-D68 was the most
frequent serotype detected (N = 191, 46.6%), followed
by EV-A71 (N = 31, 7.6%), coxackievirus (CV)–A6
(N = 25, 6.1%), echovirus (E)-30 (N = 19, 4.6%) and
E-6 (N = 12, 2.9%). Other EV types were also identified
in minor proportion (Figure 1). Overall, the distri-
bution of EV species was 46.6% for EV-D, 27.8% for
EV-B, 25.1% for EV-A and 0.5% for EV-C (Figure 1).
Epidemiological and clinical characteristics of EV-
D68 infections: comparison with EV-A or B infections.
Table 1. Panel of enterovirus (EV), parechovirus (HPeV) and





EV-A: CV-A6, CV-A16, CV-A10, EV-A71 negative
EV-B: E-5, E-6, E-9, E-11, E-13, E-20, E-30, CV-B3, CV-
B4
negative
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Overall, EV-A and B types were detected throughout
the year whereas EV-D68 was identified during the
cold months (from October to March) ranged from
20 to 54% of the total EVs in those periods. In 2016
and 2018, in addition, a high incidence of EV-D68
infections was detected between April and September
(warm months) with 121 and 22 cases which rep-
resented 74.2 and 70.9% respectively of the total EV
typed in those months (Figure 2).
In 175/191 (91.6%) EV-D68 infections, the virus
was the only known respiratory infectious agent
detected in the samples. RV, human adenovirus
(HAdV) and bocavirus (HBoV) were co-detected in
nine, three and two of the EV-D68 patients, respect-
ively. In addition, one patient was co-infected together
with HAdV and HBoV, and another with RV, HAdV
and human parainfluenza virus (HPIV). However,
coinfection with one (N = 30), two (N = 11), three (N
= 1) or even four (N = 2) respiratory viruses was ident-
ified in 44 out of 217 EV-A or B-positive patients
(20.3% vs. 8.4% in EV-D68 infections, p = 0.000001),
RV being the most frequent (N = 20). Also identified
were respiratory syncytial virus, human metapneumo-
virus, HAdV, HBoV, HPIV, human coronavirus OC43
and influenza A virus.
Clinical data were available in 346 characterized EV
infections: 172 were EV-D68-positive patients, 138
children (mean age, 3.2 ± SD 3.1 years, interquartile
range 3.3) and 34 adults (mean age 57.2 ± SD 19.1
years, interquartile range 29.8); 174 were patients
with EV-A/B infections, 164 children (mean age 2.1±
SD 2.1 years, interquartile range 2.1) and 10 adults
(mean age 65.4 ± SD 16.6 years, interquartile range
25.9). Bronchitis were more frequently diagnosed in
EV-D68-infected children compared to EV-A/EV-B-
positive patients (p < 0.01), whereas EV-A or EV-B
genotypes were mainly detected in upper respiratory
tract infections (p < 0.01) (Table 2). There were no sig-
nificant differences in the proportion of patients who
were admitted to the ICU when comparing EV-D68
with EV-A or B-positive patients (23/172, 13.4% vs
18/174 10.3%, p = 0.3904). All patients but two
admitted to ICU were children.
Regarding previous clinical history, 49 out of 346
patients had an underlying disease (leukemia, multiple
myeloma, lymphoma, cystic fibrosis, liver transplan-
tation, congenital heart disease, and asthma or recur-
rent wheezing). Of them, 28/172 patients were
infected by EV-D68 (16.3%) and 21/174 by EV-A or
B (12.1%) (p = 0.1654). Only 4 of these patients
required admission to the ICU.
EV-D68 infection in non-respiratory diseases
During the routine EV genotyping in non-respiratory
diseases (neurological, mucocutaneous and systemic
diseases), EV-D68 was identified in 11 patients with
febrile syndrome and 17 with specific neurological
Figure 1. Enterovirus genotypes detected in the respiratory specimens included in this study.
Figure 2. Seasonal distribution of EV-A, EV-B and EV-D68 infections in respiratory syndromes over the 5-year study period.
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symptoms. All patients except two were children
between one month and 13 years, and EV-D68 was
the only pathogen detected. Regarding patients with
neurological symptoms, eight children and one adult
were diagnosed with meningitis or meningoencephali-
tis and the remaining eight children were finally
described as acute flaccid paralysis (AFP) cases. In all
but two patients, EV-D68 was detected in respiratory
or/and stool samples. However, EV-D68 could be
detected in CSF samples from those two patients
(one with aseptic meningitis and one with meningoen-
cephalitis). AFP cases were notified through the
national AFP Surveillance System, all required admis-
sion to the ICU and all but two presented respiratory
symptoms previously. One child with severe menin-
goencephalitis was also in ICU. EV-D68 AFP cases
were identified throughout the study period (one case
in 2015, four cases in 2016, one case in 2017 and two
cases in 2018).
EV-D68 phylogenetic analysis. EV-D68 phylogenetic
tree in VP1 region (Figure 3) showed that almost all
Spanish sequences from 2014 to 2016 belonged to the
clade B, according to the classification previously
described [7], and were genetically related to the
majority of the strains detected in the US and Canada
outbreaks during 2014 as well as sequences isolated in
other European, American and Asian countries during
2009–2016. Spanish sequences from 2014 and 2015
clustered in subclade B2 whereas those detected in
2016 belonged to the subclade B3. However, most of
the EV-D68 sequences from 2017 and 2018 (35/51,
68.6%) clustered in the recently described subclade
D1 [28–30]. Finally, strains collected in our laboratory
before 2014 (2010–2011) fell into clade A (Figure 3).
Regarding to clinical manifestations, most neurological
cases were B3 strains although B2 or D1 were also
detected in two patients with these symptoms.
Discussion
Since 2014, an increasing number of EV-D68 out-
breaks associated with severe respiratory diseases,
mainly in children, have been occurring in different
countries, first in the US and Canada, followed by
Europe and Asia. Concurrently, clusters of cases with
neurological complications such as myelitis or acute
flaccid paralysis were reported in the same geographi-
cal areas [9–21].
In Spain, EV surveillance in respiratory infections
was not used to be routinely carried out. During
2014, however, the Enterovirus Laboratory of CNM
started receiving EV-positive respiratory samples for
genotyping. Our laboratory had already developed
tools for genotyping EV species A, B and C but not
for species D, in which serotype D68 belongs. There-
fore, a specific RT–PCR for EV-D68 was designed.
Analysis of EV-positive specimens collected from
April 2014 to December 2018 from Spanish hospital-
ized patients with respiratory illnesses confirmed the
presence of EV-D68 in almost half of the total charac-
terized EV. Other EV types from species A, B and C
were also detected at different rates. EV-A and B are
occasionally detected in respiratory samples and their
involvement in the respiratory pathology is not as
clear as in the case of EV-D68 and EV-C104, EV-
C105 or EV-C109 [2,5–16,31,32]. This is in agreement
with the fact that in our study, in most cases, EV-D68
was the single infectious agent. In EV-A and B infec-
tions, however, the number of co-infections with
other known respiratory virus was significantly higher
which could mean that in those cases, EV could be an
incidental finding. Furthermore, most of the identified
EV-A and B types were those predominantly circulat-
ing in Spain during the same period of time (data not
published). However, as there are few reports about
which EV-A or B types are presented in respiratory
symptoms, further studies are necessary to confirm
or not their involvement in those pathologies.
Although hospitals did not refer any bacterial infection
in these patients, a possible limitation of our study
could be the lack of common criteria from all of
them testing the samples searching for different viruses
or bacteria. Therefore, some coinfection positive cases
could be missing.
Regarding seasonal distribution, EV-D68 cases were
identified sporadically in cold months during the four
years of study. In 2016 and 2018, however, it circulated
almost throughout the year, with a higher incidence in
spring and summer. This seasonal distribution, in
which EV-D68 has periods of low circulation followed
by others with high incidence, has been reported in
other countries [29,30,33–35], and suggest epidemics
of EV-D68 in 2016 and 2018, which was confirmed
by phylogenetic analyses of partial VP1 sequences
showing increased genetic diversity. The phylogenetic
tree showed that most of the Spanish EV-D68
sequences detected during 2016 clustered to the
recently described lineage B3 [33], while strains from
2014 and 2015 belonged to subclade B2. Similar results
have been obtained with other studies [34,35],
suggesting that all the 2016 outbreaks would be
Table 2. Comparison of the clinical symptoms between EV-




patients (N = 172)
EV-A or B-infected





17 (9.9%) 10 (5.7%) 0.1587
Bronchiolitis 17 (9.9%) 17 (9.8%) 0.9720
Bronchitis 38 (22.1%) 11 (6.3%) 0.0000
Pneumonia 36 (20.9%) 35 (20.1%) 0.8524
Acute respiratory
distress
38 (22.1%) 27 (15.5%) 0.1205
Upper respiratory
tract infections
20 (11.6%) 62 (35.6%) 0.0000
Pharyngitis/tonsillitis 6 (3.5%) 12 (6.9%) 0.1638
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originated by the emergence of the clade B3 becoming
predominant and replacing previously circulating clade
A and subclades B1/B2. Another hypothesis might be
that EV-D68 from clade B1/B2 caused non-sympto-
matic infections whose detection would have been
underestimated since all included samples in this
study were from hospitalized patients. Furthermore,
most of the EV-D68 detected between November
2017 and December 2018 belonged to a new emerged
subclade D1 detected firstly in China in 2016 and in
Italy and France during 2018 [28–30]. These findings
indicate that although EV-D68 epidemics can be due
to the emergence of new lineages, multiple clades
have been circulating simultaneously worldwide from
2010 to the present day.
As previously reported [16], most of the EV-D68
infections were detected in young children. However,
there were also adult patients infected, half of them
older than 65. Interestingly, 66% of sequences from
2017–2018 which belonged to subclade D1 were ident-
ified in adult patients with respiratory symptoms,
suggesting a possible different epidemiology of this
Figure 3. Phylogenetic analysis of 290 EV-D68 sequences in 3´-VP1 region (445 bp) from Spain, and representatives of different
clades worldwide. MEGA 7.0 software was used to construct the neighbour joining and maximum composite likelihood tree.
Only bootstrap values > 70% are shown. EV-D68 prototype strain Fermon was used as the outgroup. Isolates are indicated by
the GenBank accession number, country and year of isolation. Spanish strains from 2014 to 2018 are represented by circles and
indicated by country abbreviation, month and year of isolation and clinical manifestation. White circles represent respiratory-associ-
ated sequences and black circles represent neurological-associated sequences. Abbreviations for clinical manifestations are as fol-
lows: R-Respiratory disease, M-Meningitis, ME-Meningoencephalitis AFP-Acute flaccid paralysis, F-Fever.
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new strain. These findings had already been observed
in previous studies [30].
Clinical data were available in most of the cases
included in this study. In other studies [16] EV-D68
was detected in patients diagnosed with different res-
piratory diseases, ranging from a common cold with
fever to basal pneumonia, but in our series, EV-D68
infection seemed to be more associated with bronchitis
than with other respiratory presentations. By contrast,
EV from species A or B were more frequently detected
in upper respiratory tract infections (p < 0.01). Also,
there was no significant difference in the proportion
of patients from each group admitted to the ICU in
contrast to those reported by other authors who
observed a higher incidence of severe disease among
patients infected by EV-D68 [33,35].
In addition to respiratory infections, EV-D68 has
been associated with neurological complications in
recent years [11,17–21]. During our study-period, this
virus was identified in 16 children and one adult with
neurological symptoms. Of them, eight were diagnosed
as AFP cases. The association between EV-D68 and
AFP or AFM is now accepted, although causality has
not yet been proven. Regardless, the recent publication
of a mouse model, in which mice inoculated with EV-
D68 developed symptoms of myelitis, as well as several
reports evaluating the evidence for a causal relationship
supported this association [36–39]. Indeed, the World
Health Organization and the Pan American Health
Organization have recently recommended testing EV-
D68 on respiratory samples in cases of AFP/AFM,
both for case management and for surveillance purposes
[40]. Furthermore, in the present study, EV-D68 was
detected in CSF specimens from two patients with
signs of meningoencephalitis, reinforcing the neurotrop-
ism of this EV. Finally, all neurological EV-D68 strains
belonged to subclades B2/B3 or D1. These emerging
genotypes are considered to have more neurotropic
potential than A or C strains [30,36,37].
In conclusion, EV-D68 infections have been
confirmed as a cause of mild lower respiratory illnesses
in Spain, mainly in children, but also in adults. Mul-
tiple clades of EV-D68 have circulated since 2010 in
our country, although one (subclade B3) becomes
prevalent in 2016 and other (D1) emerges in 2018. In
addition, EV-D68 has also been associated with severe
neurological cases, indicating the need for better sur-
veillance of this EV type in respiratory specimens at
national levels. Further studies are required to under-
stand the mechanisms of this recent emergence and
the severe disease presentations involved.
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